Tumor-Specific CircRNA-Derived Antigen Peptide Identification for Hepatobiliary Tumors
Wenwen Wang(Second Affiliated Hospital of Zhejiang University), Lei Chen(Zhuzhou Central Hospital), Dong Gao(Shenzhen Bay Laboratory), Xinyao Qiu(Hainan Tropical Ocean University), Yan Zhao(Wuhan University), Jinxia Bao(Second Military Medical University), Tinggan Yuan(ShanghaiTech University), Siyun Shen(Second Military Medical University), Peng Wang(Zhengzhou University), Yani Zhang(Yangzhou University), Xing Zheng(Xi'an University of Technology), Hongyang Wang(Second Military Medical University), Lili Ma(ShanghaiTech University), Yanjing Zhu(Shanghai Medical College of Fudan University), Yali Zong(Fudan University), Xiaofang Zhao(Fudan University Shanghai Cancer Center), Shuai Yang(Second Military Medical University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer
|Nature Communications|2018|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934